All patients |
Baseline (clinical parameters, HPV16 DNA status) |
0.76 (0.67–0.83) |
<0.01 |
0.66 (0.58–0.75) |
<0.01 |
0.69 (0.40–0.91) |
0.15 |
CD44 > 0.2 |
0.76 (0.68–0.83) |
<0.01 |
0.69 (0.60–0.77) |
<0.01 |
0.77 (0.55–0.93) |
0.02 |
SLC3A2 > −3.135 |
0.77 (0.68–0.84) |
<0.01 |
0.66 (0.56–0.76) |
<0.01 |
0.72 (0.44–0.92) |
0.10 |
MET > −4.135 |
0.78 (0.69–0.85) |
<0.01 |
0.64 (0.54–0.74) |
0.01 |
0.75 (0.50–0.92) |
0.04 |
15-gene signature |
0.80 (0.73–0.87) |
<0.01 |
0.68 (0.58–0.77) |
<0.01 |
0.74 (0.44–0.93) |
0.10 |
26-gene signature |
0.79 (0.71–0.85) |
<0.01 |
0.67 (0.58–0.75) |
<0.01 |
0.71 (0.43–0.91) |
0.11 |
CD44 > 0.2, 15-gene signature |
0.80 (0.72–0.87) |
<0.01 |
0.69 (0.60–0.78) |
<0.01 |
0.78 (0.53–0.94) |
0.04 |
SLC3A2 > −3.135, 15-gene signature |
0.81 (0.73–0.87) |
<0.01 |
0.67 (0.58–0.75) |
<0.01 |
0.76 (0.48–0.95) |
0.07 |
MET > −4.135, 15-gene signature |
0.81 (0.74–0.88) |
<0.01 |
0.66 (0.56–0.75) |
<0.01 |
0.75 (0.47–0.93) |
0.07 |
|
Patients with HPV16 DNA negative tumours |
Baseline (clinical parameters) |
0.66 (0.55–0.77) |
0.01 |
0.63 (0.54–0.71) |
0.01 |
0.60 (0.21–0.87) |
0.49 |
CD44 > 0.2 |
0.68 (0.58–0.77) |
<0.01 |
0.63 (0.53–0.73) |
0.01 |
0.70 (0.41–0.90) |
0.13 |
SLC3A2 > −3.135 |
0.69 (0.58–0.79) |
<0.01 |
0.62 (0.51–0.71) |
0.03 |
0.63 (0.26–0.89) |
0.38 |
MET > −4.135 |
0.71 (0.60–0.81) |
<0.01 |
0.58 (0.47–0.70) |
0.16 |
0.66 (0.31–0.90) |
0.25 |
15-gene signature |
0.74 (0.65–0.82) |
<0.01 |
0.64 (0.54–0.74) |
0.01 |
0.64 (0.25–0.91) |
0.36 |
26-gene signature |
0.71 (0.62–0.80) |
<0.01 |
0.62 (0.53–0.71) |
0.01 |
0.61 (0.26–0.88) |
0.42 |
CD44 > 0.2, 15-gene signature |
0.74 (0.65–0.82) |
<0.01 |
0.65 (0.54–0.74) |
0.01 |
0.69 (0.36–0.91) |
0.19 |
SLC3A2 > −3.135, 15-gene signature |
0.76 (0.68–0.84) |
<0.01 |
0.62 (0.52–0.72) |
0.03 |
0.68 (0.33–0.92) |
0.24 |
MET > −4.135, 15-gene signature |
0.76 (0.68–0.84) |
<0.01 |
0.61 (0.50–0.71) |
0.05 |
0.66 (0.29–0.91) |
0.29 |